Company: Ironwood Pharmaceuticals
Based: Cambridge, MA
Investors: Fidelity Biosciences, Venrock Associates, Polaris Venture Partners, Morgan Stanley Private Equity
Scoop: Ironwood secured $50 million in private equity financing in October. The company is using the funds to support its ongoing Phase III program for linaclotide, a treatment for irritable bowel syndrome with constipation and chronic constipation. Ironwood is also investing in its pipeline of internally discovered drug candidates, and expanding its commercial capabilities.